Delving into the Latest Updates on Rabeprazole Sodium/Metronidazole/Amoxicillin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Clofezone, Rabeprazole, Rabeprazole Sodium/Amoxicillin Hydrate/Metronidazole

+ [4]

Target

Proton pump

Action

inhibitors

Mechanism

Proton pump inhibitors, Cell wall inhibitors

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [1]

Active Indication

GastritisDuodenal UlcerHelicobacter pylori infection+ [2]

Inactive Indication

AsthmaDyspepsiaGastroesophageal Reflux+ [1]

Originator Organization

Eisai Co., Ltd.

Active Organization

Eisai Co., Ltd.

Inactive Organization

Eisai, Inc.

License Organization

Woodward Pharma Services LLC

Eisai Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Japan (15 Aug 2013),

Duodenal UlcerHelicobacter pylori infectionPurpura, Thrombocytopenic, Idiopathic+ [1]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC16H21N3O6S

InChIKeyAIPFZZHNBUVELL-YWUHCJSESA-N

CAS Registry61336-70-7

View All Structures (3)

As we know，Helicobacter pylori is closely related to many gastrointestinal diseases such as chronic gastritis, peptic ulcer disease,gastric carcinoma and gastric mucosa-associated lymphoid tissue lymphoma，as well as extra-digestive diseases such as urticaria and chronic obstructive pulmonary diseases and so on.The diagnosis of H. pylori infection is based on invasive methods requiring endoscopy and biopsy(e.g. histology, culture, rapid urease test, PCR) or on non-invasive methods (e.g. serology, 13C urea breath test, stool antigen test).Histology has the highest specificity among the others,and also allows us to determine the underlying disease and perform antibiotic sensitivity testing.Serological tests are widely available and more appropriate for epidemiological studies, their main weakness for clinical use is low specificity.The 13C urea breath test is the most accurate method in patients irrespective of age.Stool antigen testing,as a promising method, is easy to perform, and its accuracy may be improved by the use of monoclonal antibodies recently proposed for capturing H. pylori antigen in stool specimen.Sensitivity and specificity, usefulness,and limitation of tests should be considered for selection of detection methods of H. pylori. Our objective is to review the current methods that are used for the detection of H. pylori infection among patients with chronic atrophic gastritis.Except that,patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.

Start Date28 Jun 2021

Sponsor / Collaborator

The Second Affiliated Hospital Zhejiang University

NCT04565574

/ CompletedPhase 1

An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects

This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A is to evaluate the effect of food on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a strong Cytochrome P450 3A [CYP3A] inducer) on pharmacokinetics (PK) of single oral doses of E7090 in healthy participants.

Start Date16 Oct 2020

Sponsor / Collaborator

Eisai Co., Ltd.

100 Clinical Results associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

Login to view more data

100 Translational Medicine associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

Login to view more data

100 Patents (Medical) associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

Login to view more data

1,328

Literatures (Medical) associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

01 Jun 2026·BIOORGANIC CHEMISTRY

Rapid discovery of repurposed drugs targeting SARS-CoV-2 spike HR1 by DNA-encoded library screening

Article

Author: Wang, Fei ; Yang, Guang ; Yan, Lei ; Liu, Lili ; Wang, Fulian ; Xue, Qingao ; Liang, Ze ; Zhang, Yi

The membrane fusion process mediated by the SARS-CoV-2 spike protein is a key therapeutic target. Its heptad repeat 1 (HR1) domain forms a conserved trimeric groove critical for forming the fusion-competent six-helix bundle with HR2. We used DNA-encoded library screening to identify small molecules binding HR1. Hits including Rabeprazole-related compound E (Rab RCE), Omeprazole, Alvimopan, and Olmesartan were characterized. Biophysical assays confirmed binding, while computational simulations revealed distinct interaction modes, with Alvimopan showing high predicted affinity. Cell-cell fusion assays demonstrated potent inhibitory activity for Olmesartan and Rab RCE. Notably, Rabeprazole and Rab RCE showed partial antiviral activity against SARS-CoV-2 variants and HCoV-OC43, rescuing virus-induced apoptosis. Mechanistically, Rabeprazole competitively occupies the HR2-binding groove on HR1, blocking fusion. Our findings identify HR1-targeting molecules like Rabeprazole as promising leads for broad-spectrum coronaviral fusion inhibitors.

04 Mar 2026·BIOCHEMICAL JOURNAL

Post-translational modifications of triosephosphate isomerase reveal metabolic vulnerabilities in T-ALL: effect of combining dichloroacetic acid and the PPI rabeprazole

Article

Author: Gómez-Manzo, Saúl ; Martínez-Pérez, Yoalli ; De la Mora-De la Mora, Ignacio ; Hernández-Hernandez, José Manuel ; Olaya-Vargas, Alberto ; León-Avila, Gloria ; Enríquez-Flores, Sergio ; Hernández-Alcántara, Gloria ; Flores-Braulio, C. Yusiel ; González-Rubio, Fernando ; López-Herrera, Gabriela ; García-Torres, Itzhel ; Flores-López, Luis A.

Abstract:

Acute lymphoblastic leukemia, particularly the T-cell subtype, remains associated with poor outcomes in relapsed and adult patients, highlighting the need for novel therapeutic strategies. Metabolic reprogramming, especially glycolytic dependence, represents a promising target. Triosephosphate isomerase (TPI), a key glycolytic enzyme, undergoes cancer-associated post-translational modifications (PTMs), including deamidation and phosphorylation. Here, we evaluated the potential of proton pump inhibitors (PPIs), particularly rabeprazole (Rbz), to selectively target PTM-bearing TPI isoforms in Jurkat cell model. Recombinant TPI variants engineered to mimic PTMs exhibited increased reactivity toward thiol-modifying agents and higher predicted binding affinities for PPI compared with wild-type TPI. Consistent with these properties, biochemical assays demonstrated preferential inhibition of the deamidation- and phosphorylation-mimicking proteins, with Rbz significantly reducing their enzymatic activity. Native gel electrophoresis of Jurkat cells protein extracts revealed drug-induced accumulation of acidic TPI isoforms, whereas normal T lymphocytes predominantly retained unmodified TPI. Rbz selectively impaired intracellular TPI activity and viability in Jurkat cells, effects enhanced by dichloroacetate (DCA) co-treatment. This inhibition correlated with marked accumulation of methylglyoxal and advanced glycation end products. Finally, combined DCA–Rbz treatment induced extensive apoptotic death in Jurkat cells while sparing normal lymphocytes. These findings identify PTM-bearing TPI isoforms as selective metabolic vulnerabilities in Jurkat cells and support the potential repurposing of thiol-modifying agents, particularly, Rbz, as targeted antileukemic strategies.

01 Mar 2026·Current drug discovery technologies

In silico Analysis to Search for an Alternative Inhibitor of Biofilm Production by Helicobacter pylori

Article

Author: Bhattacharya, Debasmita ; Nag, Moupriya ; Gupta, Avi ; Lahiri, Dibyajit ; Gupta, Jai ; Mitra, Debanjan

Introduction::

Antibiotic Resistance is a growing concern in the current world. Regarding this, Helicobacter pylori is known to be present in the digestive tracts of human beings. In some people, the infection leads to stomach cancer. With the increasing problem of Antibiotic resistance, reports show that drugs are no longer working with the same efficacy rate as they used to. The present work is a study of the two-component Acid-Response System (ArsRS) protein, one of the key pro-teins involved in biofilm formation by H. pylori.

Methods::

In this study, an overall bioinformatics analysis was conducted of the bioactive compound, along with some FDA-approved drugs, to identify potential novel treatments for diseases associated with H. pylori. The molecular docking studies have been done with common drugs that are used for the treatment of the infection caused by H. pylori as Amoxicillin, Clarithromycin, Tetracycline, Levofloxacin, Metronidazole, Omeprazole, and Rabeprazole. Another aspect of the current study was to investigate the potential for national compounds such as Quercetin, α-mangostin, Phytol, Liquiri-tin, and D-mannitol as an alternative therapeutic agent. ADMET Analysis and toxicity assessment were done to check the pharmacokinetics of the bioactive compounds. An in silico investigation of the H. pylori protein revealed its stability and compactness.

Results::

A Higher number of intra-protein interactions increases the stability of H. pylori protein. Liquiritin emerged as an active molecule that can be used for inhibiting H. pylori biofilms. The FDA-approved drug Clarithromycin showed the highest binding energy among the synthetic group.

Discussions::

The target protein's structural and sequential analysis demonstrated how the correct number of amino acids boosts the protein's stability. The ability of bioactive chemicals to function as medications is indicated by their drug-likeness characteristics. According to toxicity evaluation, they do not have any serious effects when they come into contact with people through the environment. Liquiritin and Clarithromycin were the two top compounds that appeared as the best inhibitors.

Conclusions::

Bioactive compounds that can be used as drugs. This work will also be beneficial for the development of synthetic drugs.

5

News (Medical) associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

02 Jun 2025

·www.eisai.com

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan

For Print June 2, 2025 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the launch of “Pariet® S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn and stomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan. 1 "Pariet S" is the first proton pump inhibitor (PPI 2) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product 3, works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessive acid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief. Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical under the brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders. In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life. For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets 1 "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale 2 Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process. 3 Contains rabeprazole10mg per tablet Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 [Notes to editors] Product Outline 1. Product Name: “Pariet® S” (RX-to-OTC switch, pharmaceutical requiring guidance) 2. Ingredients: Per daily dose of one tablet: rabeprazole sodium 10mg Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate 3. Indications and Usage: Stomach pain, heartburn, and bloating (This medicine contains a proton pump inhibitor which suppresses stomach acid secretion.) 4. Dosage and Administration: Adults (15 years and older): 1 tablet once daily. Do not use this medicine consecutively for more than two weeks. 5. Packaging and Recommended Retail Price (excluding tax): Packaging: 6 tablets, Recommended retail price: 1,480 yen 6. Manufactured and marketed by: Eisai Co., Ltd. Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate Full text

Drug Approval

29 Mar 2025

·pharma.economictimes.indiatimes.com

103 drug samples fail CDSCO quality test, popular brand Telma H flagged as spurious

New Delhi: During its monthly quality review, the drug regulatory body identified 103 drug samples as ‘Not of Standard Quality’ ( NSQ ) and flagged a sample of the popular brand Telma H as ‘spurious.’ Of the 103 drug samples that failed to meet the quality standards, 47 were identified by central drug laboratories, while the remaining 56 were identified by state drug laboratories in the country. The drug sample that has been labeled as “spurious” is Telma H (Telmisartan 40mg & Hydrochlorothiazide 12.5mg), a popular brand prescribed for high blood pressure patients. As per the Union Health Ministry note, the sample was picked from West Bengal. As per the February drug alert issued by the Central Drugs Standard Control Organisation (CDSCO), the sample was manufactured in 2022 and the reason for the drug test failure as notified in the alert suggests that the sample “does not conform to I.P.” (Indian Pharmacopoeia). The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 50 brands in the country, with a moving annual total (MAT) value of around ₹447 crore. Regarding the identified spurious drug sample, the Health Ministry, in its quality review announcement, stated that the sample is “made by an unauthorized manufacturer using a brand name owned by another company. The matter is under investigation and action.” CDSCO, in its drug quality alert, has remarked that the product is purported to be spurious; however, the same is subject to the outcome of the investigation. The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The 47 NSQ samples identified by the central laboratories include Rabeprazole Tablets manufactured by Martin & Brown BioSciences Pvt. Ltd.; Paracetamol & Diclofenac Sodium Tablets manufactured by I.G. PHARMA LTD.; and Telmisartan Tablets IP by Orison Pharma International, among 44 others. Whereas, the list from state laboratories comprises Calcium & Vitamin D3 Tablets manufactured by Affy Parenterals Vill.; Phenytoin Tablets by Jackson Laboratories; and Cloprostenol Injection by Monatt Biotech, including 53 others. According to CDSCO, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; if it is an imitation of, or a substitute for, another drug; if it resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among other provisions defined under Section 17-B of the Drugs and Cosmetics Act, 1940. Whereas drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Abhijeet Singh ,

13 Jun 2024

·www.pharmaindustrial-india.com

Akums Launches Rabeprazole + Levosulpiride SR Capsules

Akums Drugs & Pharmaceuticals Ltd. announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders. GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer. “Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement. Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed. “We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement. Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

Drug Approval

100 Deals associated with Rabeprazole Sodium/Metronidazole/Amoxicillin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Rabeprazole Sodium/Metronidazole/Amoxicillin	J01CR02	DB01129

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Gastritis	Japan	Eisai Co., Ltd.	21 Nov 2013
Duodenal Ulcer	Japan	Eisai Co., Ltd.	15 Aug 2013
Helicobacter pylori infection	Japan	Eisai Co., Ltd.	15 Aug 2013
Purpura, Thrombocytopenic, Idiopathic	Japan	Eisai Co., Ltd.	15 Aug 2013
Stomach Ulcer	Japan	Eisai Co., Ltd.	15 Aug 2013

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Phase 3	United States	Eisai, Inc.	01 Sep 2002
Gastroesophageal Reflux	Phase 3	United States	Eisai, Inc.	01 Sep 2002
Dyspepsia	Phase 2	Japan	Eisai Co., Ltd.	01 Apr 2010
Nasopharyngeal Diseases	Phase 2	United States	Eisai, Inc.	01 Jun 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2019	Not Applicable	Helicobacter pylori infection	-	Quadruple therapy 10 days (QT-10)	jxaobhuqch(ukcqbvzkff) = The overall incidence of AEs was also significantly lower in the OST-14 group, compared to QT-10 and QT-14 groups (21.2%, 37.2% and 41.6% respectively, p=0.02 ) hobzhwyzzf (uewgqojiag )	Positive	01 Oct 2019
NCT02135107 (EXTEND, CTgov)	Phase 3	Gastroesophageal Reflux	517	Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily)	lrsxkvxhho = qkngawqcah fncmwxhita (devhipwdiy, rvyfwerbwh - aropochlfg) View more	-	19 Nov 2018
				Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily)	lrsxkvxhho = sembeqtzyx fncmwxhita (devhipwdiy, nswipwfdil - ipxmodxsxl) View more
NCT02135107 (EXTEND, Pubmed \| J Gastroenterol)	Phase 3	Esophagitis, Peptic Maintenance	517	Rabeprazole 10 mg q.d.	slosbekrcl(otnlgeswnk) = bqmtvoudfp vvjnhrotgh (owmhamwhxu )	-	01 Jul 2018
				Rabeprazole 10 mg b.i.d.	slosbekrcl(otnlgeswnk) = wmzeshclpn vvjnhrotgh (owmhamwhxu )
NCT01398410 (CTgov)	Phase 2/3	Stomach Ulcer	405	Rabeprazole (Rabeprazole 5 mg)	nzopavfrno = argpfqfppr rmeoxlksdd (ofphffxpkm, llwiatfxpo - fnyxshmrsr) View more	-	16 Nov 2015
				Rabeprazole (Rabeprazole 10 mg)	nzopavfrno = bmgfogdkvh rmeoxlksdd (ofphffxpkm, otohjallwi - yuacwejhnj) View more
NCT01922765 (Pubmed \| World J Gastroenterol)	Phase 4	Helicobacter pylori infection	680	Clarithromycin-based triple therapy	jyvqvruxbf(mvfigswjxe) = qemleorgip fshjidmfbb (cguhqalpbo )	-	01 Jan 2015
				Metronidazole-based triple therapy	jyvqvruxbf(mvfigswjxe) = fnohsdwkld fshjidmfbb (cguhqalpbo )
NCT00539240 (CTgov)	Phase 2/3	Pain \| Gastroesophageal Reflux	236	placebo+Rabeprazole (Arm 1)	idgzzfjsxb(friynajrgc) = zsgkmihjmp gfysyiskph (omerwlckud, 0.9) View more	-	18 Aug 2014
				placebo+Rabeprazole (Arm 2)	idgzzfjsxb(friynajrgc) = maqioglgqv gfysyiskph (omerwlckud, 2.2) View more
NCT01089543 (SAMURAI \| E3810-J081-204, CTgov)	Phase 2	Dyspepsia	338	Rabeprazole (Rabeprazole 10 mg)	uvrrkqzkpj = tqszclpcjy kvymrlnsaz (zlcjsbvvwa, eckziiumjm - cqsgxnulnk) View more	-	19 Nov 2013
				Rabeprazole (Rabeprazole 20 mg)	uvrrkqzkpj = pftcqrpmfn kvymrlnsaz (zlcjsbvvwa, fhhsrdkfiw - tyhpbxdwdj) View more
NCT01089543 (SAMURAI, Pubmed \| Aliment Pharmacol Ther)	Phase 2	Dyspepsia	392	Rabeprazole 20 mg	toseormywf(zylzjgzugu) = vxqbfbjtqe ggwoiqxtcy (nlsqyqhazu )	Positive	01 Oct 2013
				Placebo	toseormywf(zylzjgzugu) = sisohgkavj ggwoiqxtcy (nlsqyqhazu )
NCT00787891 (CTgov)	Phase 3	Gastroesophageal Reflux	127	Rabeprazole Sodium (Rabeprazole Sodium 0.5 mg/kg)	poxnhojyhi = vrmxzxkxhe eppzsnljex (atspryxwgc, toeokjtrcw - ccjdfyayyd) View more	-	11 Oct 2012
				Rabeprazole Sodium (Rabeprazole Sodium 1.0 mg/kg)	poxnhojyhi = vmylmzsmfg eppzsnljex (atspryxwgc, vjyrdvpcne - xwdazxlbqz) View more
NCT00165841 (CTgov)	Phase 2	Gastroesophageal Reflux	200	Rabeprazole 20 mg (Rabeprazole 20 mg)	ctjqyufevw(jktnbkbopt) = xyohrymfoy swpplerigr (rceehfdmss, 14.39) View more	-	03 Dec 2009
				Rabeprazole 20 mg (Placebo)	ctjqyufevw(jktnbkbopt) = cabplziual swpplerigr (rceehfdmss, 29.93) View more